Semaglutide

Ozempic Fuels Novo Nordisk

Ozempic has become synonymous with weight loss, gaining significant attention on social media for its effectiveness. Despite the presence of other competing drugs, Ozempic’s success has been pivotal in making Novo Nordisk (NYSE: NVO) one of the most valuable healthcare companies worldwide.

While Novo Nordisk’s current success is impressive, it may only be the beginning for the company, Ozempic, and its approved weight-loss treatment, Wegovy. Here’s why.

Higher Doses of Semaglutide Under Testing

Semaglutide, the active ingredient in both Ozempic and Wegovy, is the key to their effectiveness. Wegovy is essentially a higher-dose version of Ozempic, approved specifically for weight loss. Novo Nordisk is now conducting clinical trials for even higher doses of semaglutide, which could potentially enhance weight loss results.

Currently, Ozempic is administered as a 2 mg weekly injection, while Wegovy’s maximum dosage is 2.4 mg. On average, patients using these medications can lose about 15% of their body weight. However, Novo Nordisk is exploring doses as high as 16 mg. Early results from an exploratory phase 2 trial have shown promising weight loss responses and a safety profile consistent with previous semaglutide trials, according to Executive Vice President of Development Martin Lange.

Future Growth Catalysts for Novo Nordisk

Novo Nordisk’s stock has already risen about 38% this year, reflecting its strong performance. Yet, more growth opportunities lie ahead. The higher-dose semaglutide treatment is just one example. Another exciting prospect is amycretin, an oral treatment that could potentially offer even better results. In an early phase 1 trial, amycretin helped patients lose 13% of their body weight in just 12 weeks, compared to 6% with Wegovy at the same stage. Despite being in the early stages of development, amycretin holds significant promise.

Although Novo Nordisk’s growth rate has dipped recently, it remains robust at over 20%. The company is also expanding its manufacturing capabilities to address shortages of both Ozempic and Wegovy, which could lead to stronger sales figures.

A Strong Investment Opportunity

With a market capitalization nearing $640 billion, Novo Nordisk’s stock is trading at roughly 50 times earnings. However, if the company continues its strong growth trajectory while maintaining high-profit margins, its valuation is likely to improve significantly over time.

In the short term, there may be fluctuations in the share price, but the long-term growth potential makes Novo Nordisk a compelling investment. With profit margins exceeding 35% over the past 12 months, the company is well-positioned for continued success.

Considering an Investment in Novo Nordisk?

Before investing in Novo Nordisk, it’s worth noting that while the Motley Fool Stock Advisor team has identified their top 10 stock picks, Novo Nordisk didn’t make the list. The selected stocks have the potential for significant returns, as evidenced by the performance of Nvidia, which has seen massive growth since its recommendation in April 2005.

The Stock Advisor service offers a comprehensive blueprint for investment success, with regular updates and new stock picks each month, having outperformed the S&P 500 since 2002.

Investing in Novo Nordisk could be a smart move, especially if you plan to hold onto the stock for the long term. With its promising pipeline and strong financial performance, Novo Nordisk remains an excellent stock to consider.

Ozempic Users Need Better Contraception

Claims that “skinny jabs” are causing an unexpected baby boom have prompted experts to advise women to use effective contraception alongside these medications.

Drugs like Wegovy and Ozempic, which contain semaglutide, have gained immense popularity due to their ability to help users lose more than 10% of their body weight. These medications work by mimicking a hormone called GLP-1, increasing insulin production, slowing stomach digestion, and reducing appetite.

However, the rise in the use of these drugs has coincided with numerous reports of women becoming pregnant while using them—these drugs are known as GLP-1 receptor agonists. The Facebook group “I got pregnant on Ozempic” has over 750 members, and Reddit threads are filled with similar anecdotes.

Although studies confirming a direct link are lacking, experts believe the association is plausible. Dr. Karin Hammarberg of Monash University in Australia explains that women with obesity often have irregular or no periods due to anovulation. Weight loss can lead to more regular ovulation, thereby improving fertility.

Research is ongoing to investigate whether semaglutide can enhance ovulation in women with obesity and polycystic ovary syndrome (PCOS), a condition associated with irregular periods, weight gain, and infertility.

Despite potential benefits, concerns exist about the safety of using GLP-1 receptor agonists during pregnancy. A Novo Nordisk spokesperson, the manufacturer of Ozempic and Wegovy, noted that pregnancy or intention to become pregnant were exclusion criteria in their trials. Consequently, there is limited clinical trial data on semaglutide use in pregnant women.

Animal studies have indicated that semaglutide may cause fetal abnormalities. Novo Nordisk reported that pregnant rats exposed to the drug showed structural abnormalities and growth alterations in their offspring. Similar outcomes were observed in studies with rabbits and cynomolgus monkeys, with increased pregnancy loss and slight increases in fetal abnormalities at clinically relevant doses.

Novo Nordisk is conducting trials to determine the safety of these drugs for pregnant women. Meanwhile, the company advises against using semaglutide during pregnancy due to unknown effects on an unborn child. The patient information leaflet for Wegovy recommends using contraception while taking the medication and stopping its use at least two months before trying to conceive.

Despite these precautions, some women have reported pregnancies while using GLP-1 receptor agonists and hormonal contraception, sparking speculation that the drugs might interfere with birth control effectiveness.

Professor Sir Stephen O’Rahilly of the Wellcome-MRC Institute of Metabolic Science highlighted that the question of whether GLP-1 receptor agonists affect oral contraceptives remains largely unanswered. Gastrointestinal side effects like diarrhea from these drugs could potentially impair the absorption of oral contraceptives.

To mitigate the risk of unintended pregnancy, O’Rahilly suggests that women on the pill who wish to avoid pregnancy should consider using additional contraception, such as barrier methods, during active weight loss on GLP-1 receptor agonists. Once weight stabilizes, contraceptive efficacy is likely to return to normal.

Hammarberg supports this advice, noting that while anecdotal reports exist of women on semaglutide getting pregnant while on the pill, this can also happen without the medication. She advises that women on Ozempic and similar drugs use condoms or consider an IUD to ensure effective contraception.

Hormone Therapy and Weight Loss in Postmenopausal Women: The Impact of Semaglutide

Introduction

Postmenopausal women who are overweight and on hormone therapy experience more significant weight loss with the GLP-1 receptor agonist drug semaglutide compared to those not on hormone therapy, according to a recent study published in Menopause.

The Impact of Menopause on Weight and Body Composition

During menopause, up to 70% of women experience weight gain due to aging, estrogen decline, a decrease in energy, and a decrease in spontaneous physical activity. This transition is also associated with body composition changes, such as increased fat mass, decreased lean mass, and more body fat overall. These changes can increase the risk of developing cardiovascular and metabolic diseases, including type 2 diabetes, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (formerly nonalcoholic fatty liver disease), and cardiovascular disease (CVD).

Hormone Therapy and Semaglutide: Potential Benefits

Menopause hormone therapy has shown potential in partially reducing these changes, as has semaglutide, a GLP-1 receptor agonist approved for treating overweight and obesity. Semaglutide achieves an average weight loss of 15% over 68 weeks compared to other anti-obesity medications. Due to the lack of studies comparing weight loss outcomes with antiobesity therapies, including semaglutide among postmenopausal women with and without hormone therapy use, researchers conducted this cohort study to compare weight loss response and changes in cardiometabolic risk markers in postmenopausal women using semaglutide with and without hormone therapy.

Study Design and Participant Overview

The study included postmenopausal women and a retrospective review of electronic medical records (EMRs) from the Mayo Clinic Health System. Researchers examined patients using semaglutide who were overweight or obese between January 1, 2021, and March 31, 2023. Researchers compared weight loss outcomes and changes in cardiovascular and metabolic risk factors between postmenopausal women with and without systemic hormone therapy.

Menopause was defined as women aged 40 years and older with 12 months or more of no menstrual period. Women in the no-hormone therapy group never received systemic hormone therapy, while those in the hormone therapy group had started their hormones before semaglutide initiation at three months use or more and continued throughout the treatment.

The study included 16 women on hormone therapy and 90 women not on hormone therapy, ranging from 48 to 64 years old. The hormone therapy group ranged from 51 to 67 years old.

Weight Loss Outcomes and Cardiometabolic Improvements

Women on hormone therapy showed higher total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months compared to those not on therapies. For example, after 3 months, women on hormone therapy lost about 7% of their weight, while those not on hormone therapy lost about 5%. After 6 months, women on hormone therapy lost about 13% of their weight, while those not on hormone therapy lost about 9%. After 9 months, women on hormone therapy lost about 15% of their weight, while those not on hormone therapy lost about 10%. Lastly, after 12 months, women on hormone therapy lost about 16% of their weight, while those not on hormone therapy lost about 12%. Both groups showed improvements in cardiometabolic risk markers.

Study Strengths, Limitations, and Future Directions

The strengths of this study include the fresh efforts to evaluate semaglutide’s impact on postmenopausal women with or without hormone therapy and crucial data on cardiovascular and metabolic risk markers relevant to menopausal weight and health management. However, limitations exist. The study’s design can’t confirm direct links between hormone therapy and semaglutide effects or reduce other influencing factors.

While there are significant weight loss differences, the small sample size could impact the bigger picture or simply generalize results. In addition, with most participants being white, educated, and financially stable, the findings may not apply to a wider population.

To discover a better relationship between hormone therapy use and weight loss response to semaglutide in postmenopausal women, researchers suggest that future studies should incorporate the age at menopause, type of menopause, the duration and dose of hormone therapy use; data on sleep quality, quality of life, and more factors. Additionally, researchers suggest further studies investigate if there are differences in weight loss response to antiobesity medications among premenopausal, perimenopausal, and postmenopausal women not using hormone therapy.

Conclusion

The study highlights the potential benefits of combining hormone therapy with semaglutide for weight loss in postmenopausal women. Despite the limitations, the findings provide valuable insights into managing weight and associated health risks during menopause. Further research is necessary to broaden the understanding and application of these therapies across diverse populations.

Mayo Clinic Study Highlights Predictive Power of MyPhenome Hungry Gut Test

Introduction The MyPhenome Hungry Gut test, developed by Phenomix Sciences, may help predict patient responses to semaglutide, potentially reducing uncertainty in treatment outcomes for patients with obesity. This conclusion is based on results presented during the presidential plenary session at Digestive Disease Week 2024.

The Rise of Semaglutide-Based Medications Semaglutide-based medications, such as Ozempic and Wegovy, have surged in popularity due to their ability to promote weight loss. Clinical trials have shown impressive results, with patients achieving a reduction in BMI upwards of 15%. However, individual responses to these medications can vary significantly, highlighting the need for more personalized treatment approaches, especially given the rising costs and frequent shortages of the drug.

The Role of MyPhenome in Personalized Medicine

Identifying the Hungry Gut Phenotype The MyPhenome swab test leverages genetic and biological data to identify patients with the hungry gut phenotype, which can predict how well a patient might respond to semaglutide. The hungry gut phenotype is characterized by altered postprandial satiety, indicating how soon a patient may feel hungry again after eating. This information can reveal which patients are more likely to experience reduced hunger and improved blood sugar control on semaglutide, potentially leading to more successful weight management.

Study Results: MyPhenome’s Predictive Accuracy

Study Design and Participant Selection In a study to evaluate MyPhenome’s effectiveness, 84 participants with obesity who were prescribed semaglutide took the assessment. Data were analyzed using Phenomix Sciences’ Machine-Learning Gene Risk Score algorithm to determine if participants were hungry gut positive or negative.

Striking Findings The study results were striking: participants with the hungry gut phenotype lost nearly twice as much weight, achieving 19.5% total body weight loss (TBWL) compared to 10% TBWL among those without the phenotype after 12 months.

Industry Response “We are excited with the results of this independent study of Phenomix’s MyPhenome test at Mayo Clinic,” said Mark Bagnall, CEO of Phenomix Sciences, in a news release. “Demand for semaglutide marketed as Ozempic and Wegovy is at an all-time high; this study showed an ability to identify responders to semaglutide using our test. We are excited about what lies ahead in precision medicine for obesity and are hopeful our test will be a pivotal tool for clinicians across the US.”

Addressing Costs and Accessibility Issues

Rising Costs and Drug Shortages Semaglutide can cost patients around $1,000 per month out-of-pocket. Increased demand has led to persistent drug shortages, making it difficult for patients to access continuous care, which can disrupt treatment plans and lead to health complications.

MyPhenome’s Potential Impact MyPhenome aims to address these issues by optimizing the use and distribution of semaglutide. The urgency for such solutions is rising: Morgan Stanley Research predicts that the obesity drug market will surpass $77 billion by 2030, and other estimates suggest that 1 in 2 US adults will be obese by then.

Conclusion

“Our results underscore the potential of individualizing therapy to improve outcomes that will ultimately translate into improved health,” said Hurtado Andrade, MD, principal investigator of the study, in a news release.

From Diabetes Drug to Celebrity Weight-Loss Secret: The Rise of Ozempic

Ozempic (semaglutide) has transitioned from a diabetes treatment to a well-known weight-loss aid, earning a place in households across the nation. This medication belongs to a new generation of “nutrient-stimulated, hormone-based therapeutics” that mimic the body’s natural hormones. Specifically, Ozempic mimics GLP-1, a hormone produced in the gut that signals the brain when you’ve had enough to eat.

Approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes (under the brand name Ozempic) and obesity (as Wegovy), semaglutide is highly effective for both conditions. However, many patients experience side effects such as nausea and abdominal pain. Since Ozempic reduces appetite, patients often eat less, necessitating dietary adjustments to maintain proper nutrition and manage symptoms.

Foods to Avoid While Taking Ozempic

1. Greasy and Fried Foods

Foods like french fries, onion rings, and potato chips are high in fat, with more than half of their calories often coming from fat. When losing weight on Ozempic, it’s crucial to remember that muscle loss can accompany fat loss, which can be problematic. To combat muscle loss, incorporate resistance training like squats, pushups, or weight lifting at least a few times a week. Additionally, prioritize high-protein foods over high-fat foods. Healthy high-protein options include beans, lentils, nut butters, and seafood.

2. Refined Carbohydrates

Many Americans regularly consume refined carbohydrates such as white bread, white rice, white pasta, crackers, and desserts. These “calorie-dense, nutrient-poor” foods offer few health-promoting nutrients relative to their calorie content. Since Ozempic users experience reduced appetite and eat less, it’s important to choose nutrient-dense foods. Opt for starchy vegetables like sweet potatoes, corn, or peas, and whole grains like whole wheat bread, brown rice, and whole-grain pasta. Complement these with fruits, vegetables, legumes, nuts, and seeds to ensure a high nutrient intake.

3. Coffee and Alcohol

While it’s safe to consume coffee and alcohol in moderation while taking Ozempic, these beverages can be harsh on the stomach. If you’re prone to acid reflux or indigestion, drinking too much coffee or alcohol can exacerbate these issues. Ozempic slows digestion, causing food—and these beverages—to linger in the stomach longer, potentially leading to heartburn. Limit coffee to two cups per day and alcohol to one drink per day if you experience symptoms. Consider alternatives like ginger tea or water infused with sliced cucumbers and mint to soothe your stomach.

4. Big Meals

Ozempic slows down digestion, making large meals hard on your digestive system. Eating a big meal may cause bloating, nausea, or prolonged feelings of fullness. Instead, try consuming several smaller meals and snacks throughout the day. Focus on nutrient-dense snacks that combine fruits and vegetables with protein sources, such as apples with peanut butter, carrots with hummus, or plain nonfat Greek yogurt with fresh berries.

Final Thoughts

Understanding which foods to avoid can help manage the side effects of Ozempic and ensure optimal nutrition. While this medication can be highly effective for weight loss and diabetes management, combining it with a healthy diet and regular exercise is crucial for the best results.

For more information and detailed guidance, consult your healthcare provider to tailor your diet and lifestyle changes to your specific needs.

If you need Rybelsus weight loss tablets call or txt 858-952-1077.

Nutritionist Claims Certain Healthy Foods Can Mimic Weight Loss Injections

A nutritionist has revealed that regularly consuming certain healthy foods can yield slimming results similar to those achieved with weight loss injections.

In the past year, weight loss injections containing a hunger-blocking compound called semaglutide have gained significant popularity. Distributed under brand names like Wegovy and Ozempic, these medications are primarily used to treat type 2 diabetes but have also become known for their quick weight loss effects by mimicking the fullness caused by the GLP-1 hormone.

However, nutritionist Dr. Emma Beckett suggests that eating foods rich in “good fats,” such as avocados, nuts, and eggs, can naturally boost GLP-1 production in the body, making them just as effective as semaglutide injections for weight loss but without the unpleasant side effects.

Healthier Alternatives to Weight Loss Injections

Dr. Beckett explained that macronutrients found in certain foods trigger GLP-1 secretion. “There is evidence that by choosing foods high in these nutrients, GLP-1 levels can be increased,” she told Diabetes.co.uk. “This means a healthy diet, high in GLP-1 stimulating nutrients can increase GLP-1 levels. This could be foods with good fats, like avocado or nuts, or lean protein sources like eggs.”

Avocados, for instance, are packed with healthy fats that can trigger appetite-regulating hormones, making them a beneficial addition to any diet aiming for weight loss.

Potential Side Effects of Weight Loss Injections

While effective for individuals with obesity, weight loss injections can come with some unpleasant symptoms. According to the websites for Wegovy and Ozempic, regular use may cause nausea, stomach pain, constipation, and vomiting. Wegovy users may also experience headaches, tiredness, and dizziness.

Wegovy has been approved for use on the NHS for those with a Body Mass Index (BMI) of 35 and higher, but patients must have a serious weight-related condition, like type 2 diabetes, to qualify.

Notable Users and Clinical Findings

Celebrities such as Jeremy Clarkson, Elon Musk, and Chelsea Handler have openly admitted to using these drugs for weight loss. Talk show host Oprah Winfrey has also turned to these medications to shed pounds.

A study published earlier this month suggested that semaglutide injections may offer additional benefits for people who struggle to lose weight. The findings indicate that obese individuals who underwent this treatment had a lower risk of heart attack, stroke, and heart failure compared to those who took a placebo.

Clinical trials for Wegovy showed that participants with an average starting weight of 232 pounds lost about 15% of their body weight—approximately 35 pounds or 2.5 stone—over a 68-week period.

The Importance of Diet and Lifestyle Changes

Despite the benefits of weight loss injections, Dr. Beckett emphasizes that lasting health improvements require long-term dietary changes. “Using weight loss injections does not give you the go-ahead to indulge,” she says, noting that users must still commit to healthier eating habits for true health benefits.

In summary, while weight loss injections like Wegovy and Ozempic can be effective, incorporating certain healthy foods into your diet may offer similar benefits. Avocados, nuts, and eggs are just a few examples of foods that can naturally stimulate GLP-1 production, potentially aiding in weight loss without the side effects associated with medication.

For Rybelsus weight loss tablets call or txt 858-952-1077, overnight delivery available.